Positive Phase III Results Support ZIIHERA^® As HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA^® and Chemotherapy As New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

BeOne Medicines Ltd. announced positive top-line results from the Phase III HERIZON-GEA-01 trial evaluating ZIIHERA^® in combination with chemotherapy, with or without TEVIMBRA^®, as first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.